Provided by Tiger Trade Technology Pte. Ltd.

LENSAR Inc

8.39
+0.09001.08%
Volume:82.49K
Turnover:694.80K
Market Cap:103.04M
PE:15.87
High:8.54
Open:8.32
Low:8.26
Close:8.30
52wk High:12.94
52wk Low:4.95
Shares:12.28M
Float Shares:8.85M
Volume Ratio:0.72
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5288
EPS(LYR):-2.8667
ROE:357.30%
ROA:-18.66%
PB:6.91
PE(LYR):-2.93

Loading ...

Lake Street Keeps Their Buy Rating on LENSAR (LNSR)

TIPRANKS
·
Aug 25

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Lensar Posts Investor Presentation Highlighting ALLY Robotic Laser Cataract Surgery Platform

Reuters
·
Aug 18

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

TIPRANKS
·
Aug 14

U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce

Reuters
·
Aug 14

Lensar Price Target Raised to $9.00/Share from $7.00 by BTIG

Dow Jones
·
Aug 14

Lensar Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Lensar Rises After Surprise Q2 Profit, Revenue Beat

Reuters
·
Aug 13

Lensar Q2 Revenue Rises 18%, Returns to Profit

Reuters
·
Aug 13

Lensar Q2 FY26 Net Income Turns to USD 3.5 Million; Revenue Rises 18% to USD 16.5 Million

Reuters
·
Aug 13

LENSAR Q2 EPS $0.10 Beats $(0.17) Estimate, Sales $16.495M Beat $14.650M Estimate

Benzinga Earnings
·
Aug 13

Lensar Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Lensar Holds Annual Shareholder Meeting

Reuters
·
Aug 11

Lensar to Report Q2 2026 Results, Host Conference Call

Reuters
·
Aug 06

Lensar Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 03

LENSAR (LNSR) Receives a Buy from BTIG

TIPRANKS
·
Jun 24

LENSAR files Form 3 for Interim CFO Michael A. Rossi reporting no securities owned

Reuters
·
Jun 06

LENSAR names Michael Rossi interim CFO effective May 29

Reuters
·
May 30

LENSAR - Appoints Michael a. Rossi as Interim CFO Effective May 29, 2026 - SEC Filing

THOMSON REUTERS
·
May 30

Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (TMCI), NewAmsterdam Pharma Company (NAMS) and LENSAR (LNSR)

TIPRANKS
·
May 11